Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Lenacapavir, a new HIV prevention injection, will offer six months of protection per dose at a cost of Sh6,000, according to ...

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

The $400 million that the United States Congress removed from a list of programmes from which the Trump administration wants ...

Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries.